{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:05:13Z","timestamp":1789761913933,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.07.023","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:18:55Z","timestamp":1786450735000},"page":"683-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expanding indications for PARP inhibitors in prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Hanna S.","family":"Kowalewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Natalia","family":"Gandur Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8917-3263","authenticated-orcid":false,"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.urolonc.2026.07.023_bib0001","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.urolonc.2026.07.023_bib0002","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos","year":"2025","journal-title":"Ann Oncol"},{"issue":"1\u20132","key":"10.1016\/j.urolonc.2026.07.023_bib0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2023.08.001","article-title":"PARP1 roles in DNA repair and DNA replication: the basi(c)s of PARP inhibitor efficacy and resistance","volume":"51","author":"Kanev","year":"2024","journal-title":"Semin Oncol"},{"issue":"14","key":"10.1016\/j.urolonc.2026.07.023_bib0004","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.023_bib0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.07.023_bib0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.023_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2026.07.023_bib0008","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/1078-0432.CCR-19-1570","article-title":"Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression","volume":"26","author":"Chakraborty","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.023_bib0009","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.urolonc.2026.07.023_bib0010","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","article-title":"Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial","volume":"10","author":"Marshall","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.023_bib0011","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.urolonc.2026.07.023_bib0012","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.023_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.023_bib0014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.urolonc.2026.07.023_bib0015","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.urolonc.2026.07.023_bib0016","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.07.023_bib0017","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.023_bib0018","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"10398","key":"10.1016\/j.urolonc.2026.07.023_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.023_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.023_bib0021","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/oncolo\/oyae120","article-title":"TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations","volume":"29","author":"Markowski","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2026.07.023_bib0022","doi-asserted-by":"crossref","first-page":"S966","DOI":"10.1016\/j.annonc.2024.08.1682","article-title":"1601P First results from ZZFIRST: a randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-na\u00efve prostate cancer (mHNPC)","author":"Mateo","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.07.023_bib0023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2604126","article-title":"PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer","volume":"395","author":"Agarwal","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.urolonc.2026.07.023_bib0024","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus Olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.07.023_bib0025","doi-asserted-by":"crossref","first-page":"e004761","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.023_bib0026","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus Talazoparib in patients with advanced solid tumors: the JAVELIN PARP Medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.07.023_bib0027","article-title":"Multicenter Phase II study of Olaparib and the ATR inhibitor Ceralasertib in metastatic castration-resistant prostate cancer (TRAP)","volume":"9","author":"Tsung","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.023_bib0028","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"17","key":"10.1016\/j.urolonc.2026.07.023_bib0029","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1158\/1078-0432.CCR-22-2585","article-title":"A phase ib, open-label study evaluating the safety and efficacy of Ipatasertib plus Rucaparib in patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Pook","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.023_bib0030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2023.11.014","article-title":"Co-occurring BRCA2\/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer","volume":"7","author":"Orme","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:12:26Z","timestamp":1789758746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926006150"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.023","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding indications for PARP inhibitors in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}